BB-476(BB-476) - 药物靶点：HMG-CoA reductase_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

HMG-CoA reductase

作用机制

HMG-CoA reductase抑制剂(羟甲基戊二酰辅酶A合酶抑制剂)

治疗领域

内分泌与代谢疾病

在研适应症-

非在研适应症

高脂血症

原研机构

Ligand UK Ltd.

在研机构-

非在研机构

Ligand UK Ltd.

Japan Tobacco, Inc.日本烟草（香港）有限公司

最高研发阶段终止临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 BB-476 相关的临床结果

登录后查看更多信息

100 项与 BB-476 相关的转化医学

登录后查看更多信息

100 项与 BB-476 相关的专利（医药）

登录后查看更多信息

1

项与 BB-476 相关的文献（医药）

2023-06-01·Pesticide Biochemistry and Physiology

Enhanced toxicity of entomopathogenic fungi Beauveria bassiana with bacteria expressing immune suppressive dsRNA in a leaf beetle

Article

作者: Xu, Letian ; Zhang, Yuxin ; Wang, Tianjing ; Tu, Chengjie ; Yu, Jingya ; Luo, Jing ; Xu, Pei ; Sun, Liuwei ; Zhu, Peipei

The entomopathogenic fungus is recognized as an ideal alternative to chemical pesticides, nonetheless, its efficacy is often limited by insect's innate immune system. The suppression of the host immunity may overcome the obstacle and promote the toxicity of the fungi. Here, by using an entomopathogenic fungus Beauveria bassiana and immune genes dsRNA-expressing bacteria, we explored the potentially synergistic toxicity of the two agents on a leaf beetle Plagiodera versicolora (Coleoptera: Chrysomelidae). We first determined the susceptibilities of P. versicolora to a B. bassiana 476 strain (hereafter referred to Bb476). And the immune genes were identified based on the transcriptome of Bb476 challenged beetles. Subsequently, five immune genes (PGRP1, Toll1, Domeless，SPN1，and Lysozyme) were targeted by feeding dsRNA-expressing bacteria, which produced a 71.4, 39.0, 72.0, 49.0, and 68.7% gene silencing effect, respectively. Furthermore, we found a significantly increased mortality of P. versicolora when combined the Bb476 and the immune suppressive dsRNAs. Taking together, this study highlights the importance of insect immunity in the defense of entomopathogens and also paves the way toward the development of a more efficient pest management strategy that integrates both entomopathogens and immune suppressive dsRNAs.

100 项与 BB-476 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
高脂血症	临床3期	日本	Japan Tobacco, Inc.	-
高脂血症	临床前	美国	Ligand UK Ltd.	-
高脂血症	临床前	-	日本烟草（香港）有限公司	-
高脂血症	临床前	英国	Ligand UK Ltd.	-